Last updated: 05/05/2023 12:50:23

Asthma control and adherence among participants in Extended Salford Lung Study (Ex-SLS) taking Inhaled corticosteroids/Long-acting beta-agonist (ICS/LABA)

GSK study ID
214487
See study documents
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Asthma control and adherence in Ex-SLS patients prescribed ICS/LABA
Trial description: This study will assess the level of asthma control among participants in the United Kingdom (UK) who participated in the Ex-SLS, and described across asthma treatment steps, treatments prescribed and medication adherence subgroups.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Asthma Control Test (ACT) score at indicated time point

Timeframe: At index date (Day 1)

Secondary outcomes:

Asthma Control Questionnaire – 6-item (ACQ-6) score at indicated time point

Timeframe: At Index date (Day 1)

Summary of socio-demographic, clinical and asthma-related characteristics by asthma control status

Timeframe: Up to 6 months

Interventions:
Not applicable
Enrollment:
0
Primary completion date:
2022-05-05
Observational study model:
Cohort
Time perspective:
Retrospective
Clinical publications:
Not applicable
Medical condition
Asthma
Product
fluticasone furoate/vilanterol/umeclidinium bromide
Collaborators
Not applicable
Study date(s)
April 2021 to May 2022
Type
Observational
Phase
4

Participation criteria

Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
  • Participants must have questionnaire data, and valid primary care Electronic Medical Record (EMR) data.
  • Participants must have completed the ACQ-6 and ACT within the asthma questionnaire.
  • None
Inclusion and exclusion criteria
Inclusion criteria:
  • Participants must have questionnaire data, and valid primary care Electronic Medical Record (EMR) data.
  • Participants must have completed the ACQ-6 and ACT within the asthma questionnaire.
Exclusion criteria:
  • None

Trial location(s)

This study does not involve prospective enrollment of participants.

Study documents

Protocol
Available language(s): English
Download document(s)
Statistical analysis plan
Available language(s): English
Download document(s)
Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Study complete
Actual primary completion date
2022-05-05
Actual study completion date
2022-05-05

Plain language summaries

Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website